Peringatan Keamanan

Ocularly applied non-steroidal anti-inflammatory drugs may cause increased bleeding of ocular tissues (including hyphemas) in conjunction with ocular surgery.

Nepafenac

DB06802

small molecule approved investigational

Deskripsi

Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.

Struktur Molekul 2D

Berat 254.2839
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Nepafenac rapidly cross the cornea (6 times faster than diclofenac in vitro).

Metabolisme

Nepafenac (prodrug) is deaminated to amfenac (active compound) in the ciliary body epithelium, retina, and choroid by intraocular hydrolases. Subsequently, amfenac undergoes extensive metabolism to more polar metabolites involving hydroxylation of the aromatic ring leading to glucuronide conjugate formation.

Rute Eliminasi

After oral administration of 14C-nepafenac to healthy volunteers, urinary excretion was found to be the major route of radioactivity elimination, accounting for approximately 85% of the dose, while fecal excretion represented approximately 6% of the dose. Nepafenac (prodrug) and amfenac (active compound) were not quantifiable in the urine.

Interaksi Obat

155 Data
Aminosalicylic acid The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Nepafenac.
Mesalazine The risk or severity of nephrotoxicity can be increased when Mesalazine is combined with Nepafenac.
Sulfasalazine The therapeutic efficacy of Sulfasalazine can be decreased when used in combination with Nepafenac.
Diflunisal The therapeutic efficacy of Diflunisal can be decreased when used in combination with Nepafenac.
Acetylsalicylic acid The therapeutic efficacy of Acetylsalicylic acid can be decreased when used in combination with Nepafenac.
Balsalazide The therapeutic efficacy of Balsalazide can be decreased when used in combination with Nepafenac.
Olsalazine The risk or severity of nephrotoxicity can be increased when Nepafenac is combined with Olsalazine.
Bismuth subsalicylate The therapeutic efficacy of Bismuth subsalicylate can be decreased when used in combination with Nepafenac.
Dersalazine The therapeutic efficacy of Dersalazine can be decreased when used in combination with Nepafenac.
Phenyl aminosalicylate The therapeutic efficacy of Phenyl aminosalicylate can be decreased when used in combination with Nepafenac.
Methyl salicylate The therapeutic efficacy of Methyl salicylate can be decreased when used in combination with Nepafenac.
Trolamine salicylate The therapeutic efficacy of Trolamine salicylate can be decreased when used in combination with Nepafenac.
Nitroaspirin The therapeutic efficacy of Nitroaspirin can be decreased when used in combination with Nepafenac.
Aloxiprin The therapeutic efficacy of Aloxiprin can be decreased when used in combination with Nepafenac.
Guacetisal The therapeutic efficacy of Guacetisal can be decreased when used in combination with Nepafenac.
Carbaspirin calcium The therapeutic efficacy of Carbaspirin calcium can be decreased when used in combination with Nepafenac.
Choline salicylate The therapeutic efficacy of Choline salicylate can be decreased when used in combination with Nepafenac.
Thiosalicylic acid The therapeutic efficacy of Thiosalicylic acid can be decreased when used in combination with Nepafenac.
Diclofenac The risk or severity of adverse effects can be increased when Diclofenac is combined with Nepafenac.
Flurbiprofen The risk or severity of adverse effects can be increased when Flurbiprofen is combined with Nepafenac.
Bromfenac The risk or severity of adverse effects can be increased when Bromfenac is combined with Nepafenac.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Nepafenac.
Nabumetone The risk or severity of adverse effects can be increased when Nabumetone is combined with Nepafenac.
Tenoxicam The risk or severity of adverse effects can be increased when Tenoxicam is combined with Nepafenac.
Celecoxib The risk or severity of adverse effects can be increased when Celecoxib is combined with Nepafenac.
Tolmetin The risk or severity of adverse effects can be increased when Tolmetin is combined with Nepafenac.
Rofecoxib The risk or severity of adverse effects can be increased when Rofecoxib is combined with Nepafenac.
Piroxicam The risk or severity of adverse effects can be increased when Piroxicam is combined with Nepafenac.
Fenoprofen The risk or severity of adverse effects can be increased when Fenoprofen is combined with Nepafenac.
Valdecoxib The risk or severity of adverse effects can be increased when Valdecoxib is combined with Nepafenac.
Sulindac The risk or severity of adverse effects can be increased when Sulindac is combined with Nepafenac.
Etodolac The risk or severity of adverse effects can be increased when Etodolac is combined with Nepafenac.
Mefenamic acid The risk or severity of adverse effects can be increased when Mefenamic acid is combined with Nepafenac.
Naproxen The risk or severity of adverse effects can be increased when Naproxen is combined with Nepafenac.
Phenylbutazone The risk or severity of adverse effects can be increased when Phenylbutazone is combined with Nepafenac.
Meloxicam The risk or severity of adverse effects can be increased when Meloxicam is combined with Nepafenac.
Carprofen The risk or severity of adverse effects can be increased when Carprofen is combined with Nepafenac.
Suprofen The risk or severity of adverse effects can be increased when Suprofen is combined with Nepafenac.
Salicylic acid The risk or severity of adverse effects can be increased when Salicylic acid is combined with Nepafenac.
Meclofenamic acid The risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Nepafenac.
Oxaprozin The risk or severity of adverse effects can be increased when Oxaprozin is combined with Nepafenac.
Ketoprofen The risk or severity of adverse effects can be increased when Ketoprofen is combined with Nepafenac.
Ibuprofen The risk or severity of adverse effects can be increased when Ibuprofen is combined with Nepafenac.
Lumiracoxib The risk or severity of adverse effects can be increased when Lumiracoxib is combined with Nepafenac.
Magnesium salicylate The risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Nepafenac.
Salsalate The risk or severity of adverse effects can be increased when Salsalate is combined with Nepafenac.
Choline magnesium trisalicylate The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Nepafenac.
Antipyrine The risk or severity of adverse effects can be increased when Antipyrine is combined with Nepafenac.
Tiaprofenic acid The risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Nepafenac.
Etoricoxib The risk or severity of adverse effects can be increased when Etoricoxib is combined with Nepafenac.
Oxyphenbutazone The risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Nepafenac.
Niflumic acid The risk or severity of adverse effects can be increased when Niflumic acid is combined with Nepafenac.
Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Nepafenac.
Benoxaprofen The risk or severity of adverse effects can be increased when Benoxaprofen is combined with Nepafenac.
Zomepirac The risk or severity of adverse effects can be increased when Zomepirac is combined with Nepafenac.
Lornoxicam The risk or severity of adverse effects can be increased when Lornoxicam is combined with Nepafenac.
Aceclofenac The risk or severity of adverse effects can be increased when Aceclofenac is combined with Nepafenac.
Zaltoprofen The risk or severity of adverse effects can be increased when Zaltoprofen is combined with Nepafenac.
Azapropazone The risk or severity of adverse effects can be increased when Nepafenac is combined with Azapropazone.
Felbinac The risk or severity of adverse effects can be increased when Nepafenac is combined with Felbinac.
Parecoxib The risk or severity of adverse effects can be increased when Nepafenac is combined with Parecoxib.
Salicylamide The risk or severity of adverse effects can be increased when Nepafenac is combined with Salicylamide.
Kebuzone The risk or severity of adverse effects can be increased when Nepafenac is combined with Kebuzone.
Isoxicam The risk or severity of adverse effects can be increased when Nepafenac is combined with Isoxicam.
Indoprofen The risk or severity of adverse effects can be increased when Nepafenac is combined with Indoprofen.
Ibuproxam The risk or severity of adverse effects can be increased when Nepafenac is combined with Ibuproxam.
Floctafenine The risk or severity of adverse effects can be increased when Nepafenac is combined with Floctafenine.
Fenbufen The risk or severity of adverse effects can be increased when Nepafenac is combined with Fenbufen.
Etofenamate The risk or severity of adverse effects can be increased when Nepafenac is combined with Etofenamate.
Epirizole The risk or severity of adverse effects can be increased when Nepafenac is combined with Epirizole.
Loxoprofen The risk or severity of adverse effects can be increased when Nepafenac is combined with Loxoprofen.
Droxicam The risk or severity of adverse effects can be increased when Nepafenac is combined with Droxicam.
Tolfenamic acid The risk or severity of adverse effects can be increased when Nepafenac is combined with Tolfenamic acid.
Clonixin The risk or severity of adverse effects can be increased when Nepafenac is combined with Clonixin.
Propacetamol The risk or severity of adverse effects can be increased when Nepafenac is combined with Propacetamol.
Tepoxalin The risk or severity of adverse effects can be increased when Nepafenac is combined with Tepoxalin.
Flunixin The risk or severity of adverse effects can be increased when Nepafenac is combined with Flunixin.
Indobufen The risk or severity of adverse effects can be increased when Nepafenac is combined with Indobufen.
Tinoridine The risk or severity of adverse effects can be increased when Nepafenac is combined with Tinoridine.
Alclofenac The risk or severity of adverse effects can be increased when Nepafenac is combined with Alclofenac.
Fentiazac The risk or severity of adverse effects can be increased when Nepafenac is combined with Fentiazac.
Suxibuzone The risk or severity of adverse effects can be increased when Nepafenac is combined with Suxibuzone.
Bumadizone The risk or severity of adverse effects can be increased when Nepafenac is combined with Bumadizone.
Alminoprofen The risk or severity of adverse effects can be increased when Nepafenac is combined with Alminoprofen.
Bufexamac The risk or severity of adverse effects can be increased when Nepafenac is combined with Bufexamac.
Feprazone The risk or severity of adverse effects can be increased when Nepafenac is combined with Feprazone.
Difenpiramide The risk or severity of adverse effects can be increased when Nepafenac is combined with Difenpiramide.
Nifenazone The risk or severity of adverse effects can be increased when Nepafenac is combined with Nifenazone.
Lonazolac The risk or severity of adverse effects can be increased when Nepafenac is combined with Lonazolac.
Tenidap The risk or severity of adverse effects can be increased when Nepafenac is combined with Tenidap.
Bendazac The risk or severity of adverse effects can be increased when Nepafenac is combined with Bendazac.
Pranoprofen The risk or severity of adverse effects can be increased when Nepafenac is combined with Pranoprofen.
Propyphenazone The risk or severity of adverse effects can be increased when Nepafenac is combined with Propyphenazone.
Proglumetacin The risk or severity of adverse effects can be increased when Nepafenac is combined with Proglumetacin.
Ethenzamide The risk or severity of adverse effects can be increased when Nepafenac is combined with Ethenzamide.
Mofebutazone The risk or severity of adverse effects can be increased when Nepafenac is combined with Mofebutazone.
Proquazone The risk or severity of adverse effects can be increased when Nepafenac is combined with Proquazone.
Benorilate The risk or severity of adverse effects can be increased when Nepafenac is combined with Benorilate.
Pirprofen The risk or severity of adverse effects can be increased when Nepafenac is combined with Pirprofen.
Acemetacin The risk or severity of adverse effects can be increased when Nepafenac is combined with Acemetacin.

Target Protein

Prostaglandin G/H synthase 1 PTGS1
Prostaglandin G/H synthase 2 PTGS2

Referensi & Sumber

Artikel (PubMed)
  • PMID: 10850857
    Gamache DA, Graff G, Brady MT, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy. Inflammation. 2000 Aug;24(4):357-70.
  • PMID: 10850858
    Ke TL, Graff G, Spellman JM, Yanni JM: Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers. Inflammation. 2000 Aug;24(4):371-84.
  • PMID: 17189793
    Lane SS, Modi SS, Lehmann RP, Holland EJ: Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J Cataract Refract Surg. 2007 Jan;33(1):53-8.
  • PMID: 17720067
    Walters T, Raizman M, Ernest P, Gayton J, Lehmann R: In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007 Sep;33(9):1539-45.
  • PMID: 18655957
    Bucci FA Jr, Waterbury LD: Re: Pharmacokinetics and pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2008 Aug;34(8):1226; author reply 1226-7. doi: 10.1016/j.jcrs.2008.05.019.

Contoh Produk & Brand

Produk: 11 • International brands: 0
Produk
  • Ilevro
    Suspension • 3 mg/1mL • Ophthalmic • US • Approved
  • Ilevro
    Suspension / drops • 3 mg/1mL • Ophthalmic • US • Approved
  • Ilevro
    Suspension • 0.3 % w/v • Ophthalmic • Canada • Approved
  • Ilevro
    Suspension / drops • 3 mg/1mL • Ophthalmic • US • Approved
  • Nevanac
    Suspension • 1 mg/1mL • Ophthalmic • US • Approved
  • Nevanac
    Suspension / drops • 1 mg/1mL • Ophthalmic • US • Approved
  • Nevanac
    Suspension • 0.1 % w/v • Ophthalmic • Canada • Approved
  • Nevanac
    Suspension / drops • 1 mg/1mL • Ophthalmic • US • Approved
Menampilkan 8 dari 11 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul